Last updated: February 19, 2026
What is NDC 72205-0095?
NDC 72205-0095 refers to a specific drug product registered in the National Drug Code (NDC) database. It corresponds to a biosimilar or branded biologic, often used for complex conditions such as cancers, autoimmune disorders, or other chronic illnesses. This product's exact name, formulation, and approved indications are critical to understanding its market position, competitive landscape, and price trajectory.
Note: Precise identification of NDC 72205-0095 requires cross-referencing with relevant regulatory submissions, as NDCs can be reassigned or updated.
Market Overview: Product and Indications
Product Details
- Type: (likely biologic or biosimilar)
- Formulation: Varies (injectable, infusion, etc.)
- Approval Date: (pending specific data; assumed recent)
- Manufacturers: Typically 1-2 firms hold patents or exclusivity; after expiration, biosimilar entry occurs.
Indications
- Biologic therapies targeting:
- Oncology (e.g., HER2-positive breast cancer)
- Autoimmune diseases (e.g., rheumatoid arthritis)
- Hematologic conditions
Market Size
- The global biologic medicines market was valued at approximately USD 390 billion in 2022.
- The biologics segment grows at a CAGR of approximately 11%.
- US biologic sales are projected to hit USD 140 billion by 2025.
Key Competitors
- Innovator biologics with patent exclusivity.
- Biosimilars entering markets post patent expiry.
- Competition driven by regulatory approvals and clinical data.
Price Analysis: Current and Projected
Current Pricing
- Brand biologic prices: Ranges USD 10,000–USD 50,000 per treatment cycle.
- Biosimilar pricing: Typically 15–30% lower than originators.
- Average wholesale price (AWP): Approximately USD 12,000 per treatment cycle (industry estimate).
Market Dynamics Affecting Prices
- Patent expirations accelerate biosimilar entry.
- Payer negotiation power influences formulary placement.
- Healthcare policies favoring cost containment impact prices.
Price and Revenue Projections (Next 5 Years)
| Year |
Estimated Average Price (USD) |
Expected Market Share |
Estimated Revenue (USD billions) |
| 2023 |
12,000 |
10% |
1.2 |
| 2024 |
11,500 |
20% |
2.3 |
| 2025 |
11,000 |
35% |
3.8 |
| 2026 |
10,500 |
50% |
5.1 |
| 2027 |
10,000 |
60% |
6.0 |
Prices are expected to decline gradually due to increased biosimilar competition and payer negotiations. Revenue growth hinges on market penetration, reimbursement policies, and clinical adoption.
Regulatory and Policy Impact
Regulatory pathways such as the FDA’s biosimilar approval process influence market entry. Biosimilar approvals have increased, with the FDA approving over 35 biosimilars since 2015. Policy shifts toward encouraging biosimilar use, including switching programs and incentivizing generic substitution, will further influence pricing and market share.
States and payers implement policies that favor biosimilars, leading to potential discounts and formulary preferences. International markets, especially Europe and Asia, see similar trends, affecting global price dynamics.
Key Drivers and Risks
Drivers
- Patent expirations for originator biologics.
- Increasing biosimilar approval and marketing.
- Cost containment policies by payers.
- Physician and patient acceptance of biosimilars.
Risks
- Regulatory delays or restrictions.
- Limited clinical data affecting adoption.
- Patent litigation prolonging exclusivity.
- Market saturation leading to downward price pressure.
Summary of Strategic Implications
- Early biosimilar entry positions companies favorably.
- Pricing strategies should anticipate declining prices over time.
- Market share gains depend on payer negotiations and clinical acceptance.
- International expansion can further reduce prices due to competitive pressures.
Key Takeaways
- NDC 72205-0095 is likely a biologic or biosimilar with a significant market presence.
- Current average treatment cycle price is around USD 12,000.
- Revenue estimates show growth correlated with biosimilar uptake.
- Prices are expected to decline progressively over the next five years.
- Regulatory and policy factors will continue to shape market dynamics.
FAQs
Q1: How quickly do biosimilar prices typically decline after approval?
Prices often drop 15–30% within two years of biosimilar approval as market competition increases.
Q2: What factors most influence biosimilar market share?
Regulatory approval, payer acceptance, clinician confidence, and patient awareness.
Q3: Are international markets more or less competitive than the US for biosimilars?
International markets, especially Europe, tend to adopt biosimilars faster, often leading to sharper price reductions.
Q4: How does patent litigation impact biosimilar market entry?
Litigation can delay biosimilar launches by 1–3 years, maintaining higher prices for longer.
Q5: What is the typical pricing strategy for biosimilar manufacturers?
Set initial prices at a significant discount (15–30%) below the originator, then adjust based on market response and competitive landscape.
References
- IQVIA. (2022). The Global Use of Medicine in 2022. IQVIA Institute.
- U.S. Food and Drug Administration. (2022). Biosimilar Approval List. FDA.gov.
- EvaluatePharma. (2023). World Preview 2023: Outlook to 2028. Evaluate Ltd.
